Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary

Abstract

Background: Neuroendocrine tumors (NETs) are rare tumors that can originate from any part of the body. Often,<br />imaging or exploratory surgery can assist in the identification of the tumor primary site, which is critical to the<br />management of the disease. Neuroendocrine tumors (NETs) of unknown primary constitute approximately 10-15%<br />of all NETs. Determining the original site of the tumor is critical to providing appropriate and effective treatment.<br />Methods: We performed a retrospective review of neuroendocrine tumors at our institution between 2012 and 2016<br />using a 92-gene cancer ID analysis. Results: 56 patients with NETs of unknown primary were identified. Samples<br />for 38 of the 56 underwent the 92-gene cancer ID analysis. The primary site of the tumor was identified with >95%<br />certainty in 35 of the 38 patients. Conclusion: The 92-gene cancer ID analysis identified a primary site in 92% of our<br />NETs study cohort that previously had been unknown. The results have direct implications on management of patients<br />with regard to FDA-approved treatment options.